최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.21 no.5 = no.133, 2011년, pp.647 - 655
박선행 (부산대학교 한의학전문대학원 경락구조의학부) , 김지현 (부산대학교 한의학전문대학원 경락구조의학부) , 배순식 (부산대학교 의학전문대학원 약리학교실) , 홍기환 (부산대학교 의학전문대학원 약리학교실) , 최병태 (부산대학교 한의학전문대학원 경락구조의학부) , 신화경 (부산대학교 한의학전문대학원 경락구조의학부)
The neurotoxicity of aggregated amyloid
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Agostinho, P., J. P. Lopes, Z. Velez, and C. R. Oliveira. 2008. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem. Int. 52, 1226-1233.
Arai, H. and T. Takahashi. 2009. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am. J. Geriatr. Psychiatry 17, 353-354.
Bermpohl, D., Z. You, E. H. Lo, H. H. Kim, and M. J. Whalen. 2007. TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. J. Cereb. Blood Flow Metab. 27, 1806-1818.
Camacho, I. E., L. Serneels, K. Spittaels, P. Merchiers, D. Dominguez, and B. De Strooper. 2004. Peroxisome-proliferator- activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24, 10908-10917.
Escribano, L., A. M. Simon, A. Perez-Mediavilla, P. Salazar-Colocho, J. Del Rio, and D. Frechilla. 2009. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 379, 406-410.
Hardy, J. 1997. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154-159.
Hardy, J. 2006. A hundred years of Alzheimer's disease research. Neuron 52, 3-13.
Hardy, J. and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
Harkany, T., T. Hortobagyi, M. Sasvari, C. Konya, B. Penke, P. G. Luiten, and C. Nyakas. 1999. Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 963-1008.
Heneka, M. T., M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G. E. Landreth. 2005. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
Hensley, K., J. M. Carney, M. P. Mattson, M. Aksenova, M. Harris, J. F. Wu, R. A. Floyd, and D. A. Butterfield. 1994. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 3270-3274.
Hong, K. W., J. H. Lee, K. Y. Kima, S. Y. Park, and W. S. Lee. 2006. Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr. Pharm. Des. 12, 565-573.
Inestrosa, N. C., J. A. Godoy, R. A. Quintanilla, C. S. Koenig, and M. Bronfman. 2005. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 304, 91-104.
Jang, J. H. and Y. J. Surh. 2002. beta-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann. N Y Acad. Sci. 973, 228-236.
Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
Kaskie, B. and M. Storandt. 1995. Visuospatial deficit in dementia of the Alzheimer type. Arch. Neurol. 52, 422-425.
Lazennec, G., L. Canaple, D. Saugy, and W. Wahli. 2000. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 14, 1962-1975.
Lee, J. H., S. Y. Park, Y. W. Shin, K. W. Hong, C. D. Kim, S. M. Sung, K. Y. Kim, and W. S. Lee. 2006. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 1082, 182-191.
Luna-Medina, R., M. Cortes-Canteli, M. Alonso, A. Santos, A. Martinez, and A. Perez-Castillo. 2005. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 280, 21453-21462.
Mogi, M., J. M. Li, K. Tsukuda, J. Iwanami, L. J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi. 2008. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem. Biophys. Res. Commun. 375, 446-449.
Nitta, A., A. Itoh, T. Hasegawa, and T. Nabeshima. 1994. beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170, 63-66.
Park, S. Y., J. H. Lee, K. Y. Kim, E. K. Kim, S. J. Yun, C. D. Kim, W. S. Lee, and K. W. Hong. 2008. Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription. Atherosclerosis 201, 258-265.
Park, S. Y., H. K. Shin, J. H. Lee, C. D. Kim, W. S. Lee, B. Y. Rhim, and K. W. Hong. 2009. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J. Pharmacol. Exp. Ther. 329, 571-579.
Pedersen, W. A., P. J. McMillan, J. J. Kulstad, J. B. Leverenz, S. Craft, and G. R. Haynatzki. 2006. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199, 265-273.
Pike, C. J., A. J. Walencewicz-Wasserman, J. Kosmoski, D. H. Cribbs, C. G. Glabe, and C. W. Cotman. 1995. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
Risner, M. E., A. M. Saunders, J. F. Altman, G. C. Ormandy, S. Craft, I. M. Foley, M. E. Zvartau-Hind, D. A. Hosford, and A. D. Roses. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254.
Rosen, E. D., P. Sarraf, A. E. Troy, G. Bradwin, K. Moore, D. S. Milstone, B. M. Spiegelman, and R. M. Mortensen. 1999. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611-617.
Selkoe, D. J. 2000. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N Y Acad. Sci. 924, 17-25.
Sung, S. M., D. S. Jung, C. H. Kwon, J. Y. Park, S. K. Kang, Y. K. Kim. 2007. Hypoxia/reoxygenation stimulates proliferation through PKC-dependent activation of ERK and Akt in mouse neural progenitor cells. Neurochem. Res. 32, 1932-1939.
Takeda, S., N. Sato, K. Niisato, D. Takeuchi, H. Kurinami, M. Shinohara, H. Rakugi, M. Kano, and R. Morishita. 2009. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Res. 1280, 137-147.
Watanabe, M., K. Inukai, H. Katagiri, T. Awata, Y. Oka, and S. Katayama. 2003. Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 300, 429-436.
Watson, G. S., B. A. Cholerton, M. A. Reger, L. D. Baker, S. R. Plymate, S. Asthana, M. A. Fishel, J. J. Kulstad, P. S. Green, D. G. Cook, S. E. Kahn, M. L. Keeling, and S. Craft. 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13, 950-958.
Yan, Q., J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A. L. Biere, M. Citron, and G. Landreth. 2003. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509.
Yang, J., X. Liu, K. Bhalla, C. N. Kim, A. M. Ibrado, J. Cai, T. I. Peng, D. P. Jones, and X. Wang. 1999. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 1129-1132.
Yankner, B. A., L. K. Duffy, and D. A. Kirschner. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279-282.
Zhang, H. Y., Y. H. Liu, H. Q. Wang, J. H. Xu, and H. T. Hu. 2008. Puerarin protects PC12 cells against beta-amyloid- induced cell injury. Cell Biol. Int. 32, 1230-1237.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.